Proteasome Inhibition in Myelodysplastic Syndromes and Acute Myelogenous Leukemia Cell Lines

REFERENCES

• Wu WK, Cho CH, Lee CW, Wu K, Fan D, Yu J, Sung JJ. Proteasome inhibition: a new therapeutic strategy to cancer treatment. Cancer Lett 2010;293:15–22.
   PubMed Web of Science ®Google Scholar
• Navon A, Ciechanover A. The 26 S proteasome: from basic mechanisms to drug targeting. J Biol Chem 2009;284:33713–33718.
   PubMed Web of Science ®Google Scholar
• Guzman ML, Neering SJ, Upchurch D, Grimes B, Howard DS, Rizzieri DA, Luger SM, Jordan CT. Nuclear factor-kB is constitutively activated in primitive human acute myelogenous leukemia cells. Blood 2001;98:2301–2307.
   PubMed Web of Science ®Google Scholar
• Cilloni D, Martinelli G, Messa F, Baccarani M, Saglio G. Nuclear factor kB as a target for new drug development in myeloid malignancies. Haematologica 2007;92:1224–1229.
   PubMed Web of Science ®Google Scholar
• Karin M, Greten FR. NF-κB: linking inflammation and immunity to cancer development and progression. Nat Rev 2005;5:749–759.
   Google Scholar
• Servida F, Soligo D, Delia D, Henderson C, Bracolini C, Lombardi L, Delliers GL. Sensitivity of human multiple myelomas and myeloid leukemias to the proteasome inhibitor I. Leukemia 2005;19:2324–2331.
   PubMed Web of Science ®Google Scholar
• Dasmahapatra G, Rahmani M, Dent P, Grant S. The tryphostin adaphostin interacts synergistically with proteasome inhibitors to induce apoptosis in human leukemia cells through a reactive oxygen species (ROS)-dependent mechanism. Blood 2006;107:323–340.
   Google Scholar
• Moore HE, Davenport EL, Smith EM, Muralikrishnan S, Dunlop AS, Waler BA, Drige D, Drummond AH, Hooftman L, Morgan GJ, Davies FE. Aminopeptidase inhibition as a targeted treatment strategy in myeloma. Mol Cancer Ther 2009;8:762–770.
   PubMed Web of Science ®Google Scholar
• Braun T, Carvalho G, Coquelle A, Vozenin M-C, Lepelley P, Hirsch F, Kiladjian J-J, Ribrag V, Fenaux P, Kroemer G. NF-KB constitutes a potential therapeutic target in high-risk myelodysplastic syndrome. Blood 2006;107:1156–1165.
   PubMed Web of Science ®Google Scholar
• Sanz GF, Sanz MA, Greenberg PA. Prognostic factors and scoring systems in myelodysplastic syndromes. Haematologica 1998;83:358–368.
   PubMed Web of Science ®Google Scholar
• Liesveld JL, Jordan CT, Phillips GL II. The hematopoietic stem cell in myelodysplasia. Stem Cells 2004;22:590–599.
   PubMed Web of Science ®Google Scholar
• Anderson KC. Targeted therapy of multiple myeloma based upon tumor-microenvironmental interaction. Exp Hematol 2007;35:156–162.
   Google Scholar
• Hideshima T, Chauhan D, Hayashi T, Akiyama M, Mitsiades N, Mitsiades C, Podar K, Munshi NC, Richardson PG, Anderson KC. Proteasome inhibitor PS-341 abrogates IL-6 triggered signaling cascades via caspase-dependent downregulation of gp130 in multiple myeloma. Oncogene 2003;20:8386–8393.
   Google Scholar
• Shetty V, Verspoor F, Nguyen H, Gallegos A, Mundle S, Chaudhry N, Imran M, Mahmud G, Mumtaz M, Candoni A, Yousiff M, Alvi S, Reddy PL, Galili N, Gezer S, Venugopal P, Raza A. Effect of proteasome inhibition by bortezomib on tumor necrosis factor alpha (TNF-alpha) and apoptosis in patients with myelodysplastic syndromes (MDS). Blood 2003;102:422a.
   Web of Science ®Google Scholar
• Cheson BD, Bennett JM, Kantarjian H, Pinto A, Schiffer CA, Nimer SD, Lowenberg B, Beran M, deWitte TM, Stone RM, Mittleman M, Sanz GF, Oijermans PW, Gore S, Greenberg PL. Report of an international working group to standardize response criteria for myelodysplastic synderomes. Blood 2000;96:3671–3674.
   PubMed Web of Science ®Google Scholar
• Liesveld JL, Rosell KE, Lu C, Bechelli J, Phillips G, Lancet JE, Abboud CN. Acute myelogenous leukemia—microenvironment interactions: role of endothelial cells and proteasome inhibition. Hematology 2005;10:463–494.
   Google Scholar
• Mathas S, Lietz A, Janz M, Hinz M, Jundt F, Scheidereit C, Bommert K, Dorken B. Inhibition of NF-kappaB essentially contributes to arsenic-induced apoptosis. Blood 2003;102:1028–1034.
   PubMed Web of Science ®Google Scholar
• Karp JE, Lancet JE. Tipifarnib in the treatment of newly diagnosed acute myelogenous leukemia. Biologics 2008;2:491–500.
   PubMedGoogle Scholar
• Silverman LR. DNA methyltransferase inhibitors in myelodysplastic syndrome. Best Pract Res Clin Haematol 2004;17:585–594.
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Oki Y, Garcia-Manero G, Huang X, O'Brien S, Cortes J, Faderl S, Bueso-Ramos C, Ravandi F, Estrov Z, Ferrojoli A, Wierda W, Shan J, Davis J, Giles F, Saba HI, Issa J-P J. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood 2007;109:52–57.
   PubMed Web of Science ®Google Scholar
• List A, Kurtin S, Roe DJ, Buresh A, Mahadevan D, Fuchs D, Rimsza L, Heaton R, Knight R, Zeldis JB. Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med 2005;352:549–557.
   PubMed Web of Science ®Google Scholar
• Stapnes C, Doskeland AP, Hatfield K, Ersvaer E, Ryningen A, Lorens JB, Gjertsen BT, Bruserud O. The proteasome inhibitors bortezomib and PR-171 have antiproliferative and proapoptotic effects on primary human acute myeloid leukaemia cells. Br J Haematol 2007;136:814–828.
   PubMed Web of Science ®Google Scholar
• Riccioni R, Senese M, Diverio D, Riti V, Buffolino S, Mariani G, Boe A, Cedrone M, Coco F, Foa R, Peschle C, Testa U. M4 and M5 acute myeloid leukaemias display a high sensitivity to bortezomib-mediated apoptosis. Br J Haematol 2007;139:194–205.
   PubMed Web of Science ®Google Scholar
• Kraus M, Ruckrich T, Reich M, Gogel J, Beck A, Kammer W, Berkers CR, Burg D, Overkleeft H, Ovaa H, Driessen C. Activity patterns of proteasome subunits reflect bortezomib sensitivity of hematologoic malignancies and are variable in primary human leukemia cells. Leukemia 2007;21:84–92.
   PubMed Web of Science ®Google Scholar
• Matondo M, Bousquet-Dubouch MP, Gallay N, Utternweiler-Joseph S, Recher C, Payrastre B, Manenti S, Monsarrat B, Burlet-Schiltz O. Proteasome inhibitor-induced apoptosis in acute myeloid leukemia: a correlation with the proteasome status. Leuk Res 2010;34:498–506.
   PubMed Web of Science ®Google Scholar
• Minderman H, Zhou Y, O'Loughlin KL, Baer MR. Bortezomib activity and in vitro interactions with anthracyclines and cytarabine in acute myeloid leukemia cells are independent of multidrug resistance mechanisms and p53 status. Cancer Chemother Pharmacol 2007;60:245–55.
   PubMed Web of Science ®Google Scholar
• Attar EC, Donohue KA, Amrein PC, Wadleigh M, DeAngelo DJ, Kolitz JE, Powell BL, Voorhess PM, Wang ES, Blum W, Booth A, Stone RM, Moser BK, Larson R. Phase II study of bortezomib added to standard daunorubicin and cytarabine induction and dose escalation of bortezomib with intermediate-dose cytarabine consolidation therapy for patients with previously untreated acute myeloid leukemia age 60–75 years: cancer and leukemia group B. (CALGB) study 10502. Blood 2010;116:150a.
   Web of Science ®Google Scholar
• Gil L, Styczynski J, Dytfeld D, Debski R, Kazmierczak M, Kolodziej B, Rafinska B, Kubicka M, Nowicki A, Komarnicki M, Wysocki M. Activity of bortezomib in adult de novo and relapsed acute myeloid leukemia. Anticancer Res 2007;27:4021–4025.
   PubMed Web of Science ®Google Scholar
• Howard D, Liesveld J, Phillips GL, Guzman ML, Jordan CT. A phase I study using Bortezomib with weekly idarubicin for the treatment of elderly (>60 years) and relapsed patients with acute myeloid leukemia (AML). Blood 2008;112:1014a (abstract)
   Web of Science ®Google Scholar
• Nawrocki ST, Carew JS, Maclean KH, Courage JF, Huang P, Houghton JA, Cleveland JL, Giles FJ, McConkey DJ. Myc regulates aggresome formation, the induction of Noxa, and apoptosis in response to the combination of bortezomib and SAHA. Blood 2008;112:2917–2926.
   PubMed Web of Science ®Google Scholar
• Yu C, Rahmani M, Conrad D, Subler M, Dent P, Grant S. The proteasome inhibitor bortezomib interacts synergistically with histone deacetylase inhibitors to induce apoptosis in Bcr/Abl + cells sensitive and resistant to STI571. Blood 2003;102:2765–3774.
   Google Scholar
• Pigneux A, Mahon FX, Moreau-Gaudry F, Uhalde M, de Vermeuil H, Lacombe F, Reiffers J, Milipied N, Praloran V, Belloc F. Proteasome inhibition specifically sensitizes leukemic cells to anthracycline-induced apoptosis through the accumulation of Bim and Bax pro-apoptotic proteins. Cancer Biol Ther 2007;6:603–11.
   PubMed Web of Science ®Google Scholar
• Hamada A, Kawaguchi T, Nakano M. Clinical pharmacokinetics of cytarabine formulations. Clin Pharmacokinet 2002;4:705–718.
   Google Scholar
• Conticello C, Adamo L, Vicari L, Giuffrida R, Iannolo G, Anastasi G, Canuso L, Moschetti G, Cupri A, Palumbo GA, Gulisano M, De Maria R, Giustolisi R, DiRaimondo F. Antitumor activity of bortezomib alone and in combination with TRAIL in human acute myeloid leukemia. Acta Haematol 2008;120:19–30.
   PubMed Web of Science ®Google Scholar
• Collison A, Foster PS, Mattes J. Emerging role of tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) as a key regulator of inflammatory responses. Clin Exp Pharacol Physiol 2009;36:1049–1053.
   PubMed Web of Science ®Google Scholar
• Fabre C, Carvalho G, Tasdemir E, Braun T, Ades L, Grosjean J, Boehrer S, Metivier D, Souquere S, Pierron G, Fenaux P, Kroemer G. NF-kappaB inhibition sensitizes to starvation-induced cell death in high-risk myelodysplastic syndrome and acute myeloid leukemia. Oncogene 2007;26:4071–4083.
   PubMed Web of Science ®Google Scholar
• Hu Y, Jin X, Snow ET. Effect of arsenic on transcription factor AP-1 and NF-kappaB DNA binding activity and related gene expression. Toxicol Lett 2002;133:33–45.
   PubMed Web of Science ®Google Scholar
• Armand J-P, Burnett AK, Drach J, Harousseau J-L, Lowenberg B, San Miguel J. The emerging role of targeted therapy for hematologic malignancies: update on bortezomib and tipifarnib. The Oncologist 2007;12:281–290.
   PubMed Web of Science ®Google Scholar
• Yanamandra N, Colaco NM, Parquet NA, Buzzeo RW, Boulware D, Wright G, Perez LE, Dalton WS, Beaupre DM. Tipifarnib and bortezomib are synergistic and overcome cell adhesion—mediated drug resistance in multiple myeloma and acute myeloid leukemia. Clin Cancer Res 2006;12:591–599.
   PubMed Web of Science ®Google Scholar
• Richardson PG, Mitsiades CS, Hideshima T, Anderson KC. Novel biological therapies for the treatment of multiple myeloma. Best Pract Res Haematol 2005;18:619–634.
   PubMed Web of Science ®Google Scholar
• Reikvam H, Hatfield KJ, Lassalle P, Kittang AO, Ersvaer E, Bruserud O. Targeting the angiopoietin (Ang)/Tie-2 pathways in the crosstalk between acute myeloid leukaemia and endothelial cells: studies of Tie-2 blocking antibodies, exogenous Ang-2 and inhibition of constitutive agonistic Ang-2 release. Expert Opin Investig Drugs 2010;19:169–183.
   PubMed Web of Science ®Google Scholar